Gastrointestinal Cancer Research From ESMO 2019

This week, we discuss two studies in gastrointestinal cancers presented at this year's European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we'll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We'll hear from the lead authors of each of these studies, and we'll also hear a discussion about the use of cabozantinib in advanced hepatocellular carcinoma, with Dr. Tim Meyer and Dr. Lorenza Rimassa, co-investigators for the CELESTIAL trial.

Coverage of stories discussed this week on ascopost.com:

ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer

ESMO 2019: Ivosidenib in IDH1-Mutated Advanced Cholangiocarcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we discuss two studies in gastrointestinal cancers presented at this year's European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we'll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We'll hear from the lead authors of each of these studies, and we'll also hear a discussion about the use of cabozantinib in advanced hepatocellular carcinoma, with Dr. Tim Meyer and Dr. Lorenza Rimassa, co-investigators for the CELESTIAL trial.

This week, we discuss two studies in gastrointestinal cancers presented at this year's European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we'll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We'll hear from the lead authors of each of these studies, and we'll also hear a discussion about the use of cabozantinib in advanced hepatocellular carcinoma, with Dr. Tim Meyer and Dr. Lorenza Rimassa, co-investigators for the CELESTIAL trial.

Coverage of stories discussed this week on ascopost.com:

ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer

ESMO 2019: Ivosidenib in IDH1-Mutated Advanced Cholangiocarcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we discuss two studies in gastrointestinal cancers presented at this year's European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we'll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We'll hear from the lead authors of each of these studies, and we'll also hear a discussion about the use of cabozantinib in advanced hepatocellular carcinoma, with Dr. Tim Meyer and Dr. Lorenza Rimassa, co-investigators for the CELESTIAL trial.

Coverage of stories discussed this week on ascopost.com:

ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer

ESMO 2019: Ivosidenib in IDH1-Mutated Advanced Cholangiocarcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer

This week, we discuss two studies in gastrointestinal cancers presented at this year's European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we'll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We'll hear from the lead authors of each of these studies, and we'll also hear a discussion about the use of cabozantinib in advanced hepatocellular carcinoma, with Dr. Tim Meyer and Dr. Lorenza Rimassa, co-investigators for the CELESTIAL trial.

Coverage of stories discussed this week on ascopost.com:

ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer

ESMO 2019: Ivosidenib in IDH1-Mutated Advanced Cholangiocarcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> ESMO 2019: Ivosidenib in IDH1 Mutated Advanced Cholangiocarcinoma